Seaport Therapeutics Inc
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
101 Seaport Blvd, Boston, Massachusetts,...Phone Number
(617) 807-4062Website
www.seaporttx.comRevenue
-Industry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Seaport Therapeutics Inc
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders.Explore more
Seaport Therapeutics Inc Org Chart
Get the full picture
Sign in to uncover key details.
ER
Vice President & Head of Drug Safety Pharmaco...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Seaport Therapeutics Inc your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Seaport Therapeutics Inc recently announced quarterly report
Check if Seaport Therapeutics Inc has recently received funding, and reach out quickly before it becomes old news!
Check out if Seaport Therapeutics Inc is spiking on competitors!
Product Launch: Get notified when Seaport Therapeutics Inc launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Seaport Therapeutics Inc, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Seaport Therapeutics Inc had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Seaport Therapeutics Inc has new funding data
Congratulate Masked Content for being promoted to Masked Content at Seaport Therapeutics Inc
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Seaport Therapeutics Inc is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Seaport Therapeutics Inc is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Seaport Therapeutics Inc.
Seaport Therapeutics Inc financials insights
Gather financial insights about Seaport Therapeutics Inc, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$100M
Series B
$225M
Seaport Therapeutics Inc Tech Stack
A closer look at the technologies used by Seaport Therapeutics Inc
See more technologies
Most Recent Scoops
Person-Based
Proof of Concept (POC), Medical Research
Person-Based
Events, Finance, Investor Relations
Open Position
Open Position
Open Position
Seaport Therapeutics Inc News & Media
Seaport CEO's 'rationale behind going public' with $255M IPO - Fierce Biotech
If you’re looking for a sign that biotech’s IPO renaissance remains on track then the pair of upsized Nasdaq listings on Friday morning is a good place to start. | "We want to develop those programs as far as we can ourselves,” Seaport CEO Daphne Zohar told Fierce.Seaport Therapeutics raises about $255 million in upsized IPO - WTAQ
April 30 (Reuters) - Drug developer Seaport Therapeutics said on Thursday it had raised about $255 million in its upsized initial public offering in the United States. Here are the details: • The company sold 14.16 million shares at $18 apiece, the c...Two biotechs raise a combined $556M in latest spurt of IPOs
Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a stretch of large IPOs this year that collectively raised almost $3.2 billion.StockWatch: Revolution's Phase III Pancreatic Cancer Data Dazzles Investors, Analysts
Revolution Medicine has wowed investors and analysts by announcing dazzling data from its Phase III RASolute 302 trial (NCT06625320) evaluating its once-daily oral daraxonrasib in previously-treated patients with metastatic pancreatic cancer.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Seaport Therapeutics Inc
Sign Up For FreeTo access detailed company insights
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. Al... Read More
